 | • レポートコード：MRC2312MG09559 • 出版社/出版日：Market Monitor Global / 2023年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、72ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥471,250 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥706,875 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の13価肺炎球菌多糖体複合体ワクチン市場規模と予測を収録しています。・世界の13価肺炎球菌多糖体複合体ワクチン市場：売上、2018年-2023年、2024年-2029年 ・世界の13価肺炎球菌多糖体複合体ワクチン市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の13価肺炎球菌多糖体複合体ワクチン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「バイアル」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 13価肺炎球菌多糖体複合体ワクチンのグローバル主要企業は、Pfizer、 Kangtai、 Walvax Biotechnologyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、13価肺炎球菌多糖体複合体ワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の13価肺炎球菌多糖体複合体ワクチン市場：タイプ別、2018年-2023年、2024年-2029年 世界の13価肺炎球菌多糖体複合体ワクチン市場：タイプ別市場シェア、2022年 ・バイアル、充填済み 世界の13価肺炎球菌多糖体複合体ワクチン市場：用途別、2018年-2023年、2024年-2029年 世界の13価肺炎球菌多糖体複合体ワクチン市場：用途別市場シェア、2022年 ・病院、診療所、CDC 世界の13価肺炎球菌多糖体複合体ワクチン市場：地域・国別、2018年-2023年、2024年-2029年 世界の13価肺炎球菌多糖体複合体ワクチン市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における13価肺炎球菌多糖体複合体ワクチンのグローバル売上、2018年-2023年 ・主要企業における13価肺炎球菌多糖体複合体ワクチンのグローバル売上シェア、2022年 ・主要企業における13価肺炎球菌多糖体複合体ワクチンのグローバル販売量、2018年-2023年 ・主要企業における13価肺炎球菌多糖体複合体ワクチンのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Pfizer、 Kangtai、 Walvax Biotechnology ************************************************************* ・調査・分析レポートの概要 13価肺炎球菌多糖体複合体ワクチン市場の定義 市場セグメント 世界の13価肺炎球菌多糖体複合体ワクチン市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の13価肺炎球菌多糖体複合体ワクチン市場規模 世界の13価肺炎球菌多糖体複合体ワクチン市場規模：2022年 VS 2029年 世界の13価肺炎球菌多糖体複合体ワクチン市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの13価肺炎球菌多糖体複合体ワクチンの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の13価肺炎球菌多糖体複合体ワクチン製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：バイアル、充填済み 13価肺炎球菌多糖体複合体ワクチンのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、診療所、CDC 13価肺炎球菌多糖体複合体ワクチンの用途別グローバル売上・予測 ・地域別市場分析 地域別13価肺炎球菌多糖体複合体ワクチン市場規模 2022年と2029年 地域別13価肺炎球菌多糖体複合体ワクチン売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Pfizer、 Kangtai、 Walvax Biotechnology ... |
This research report provides a comprehensive analysis of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market, focusing on the current trends, market dynamics, and future prospects. The report explores the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, challenges faced by the industry, and potential opportunities for market players.
The global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. Additionally, the growing consumer demand present avenues for market expansion.
The global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market.
Market Overview: The report provides a comprehensive overview of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Vials, Pre-filled), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Vials
Pre-filled
Market segment by Application
Hospital
Clinic
CDC
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Pfizer
Kangtai
Walvax Biotechnology
Outline of Major Chapters:
Chapter 1: Introduces the definition of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, market overview.
Chapter 2: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Overall Market Size
2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size: 2022 VS 2029
2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales: 2018-2029
3 Company Landscape
3.1 Top 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Players in Global Market
3.2 Top Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Companies Ranked by Revenue
3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Companies
3.4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Companies
3.5 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Players in Global Market
3.8.1 List of Global Tier 1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size Markets, 2022 & 2029
4.1.2 Vials
4.1.3 Pre-filled
4.2 By Type – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue & Forecasts
4.2.1 By Type – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2018-2023
4.2.2 By Type – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2024-2029
4.2.3 By Type – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share, 2018-2029
4.3 By Type – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales & Forecasts
4.3.1 By Type – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2018-2023
4.3.2 By Type – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2024-2029
4.3.3 By Type – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share, 2018-2029
4.4 By Type – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 CDC
5.2 By Application – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue & Forecasts
5.2.1 By Application – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2018-2023
5.2.2 By Application – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2024-2029
5.2.3 By Application – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share, 2018-2029
5.3 By Application – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales & Forecasts
5.3.1 By Application – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2018-2023
5.3.2 By Application – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2024-2029
5.3.3 By Application – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share, 2018-2029
5.4 By Application – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2022 & 2029
6.2 By Region – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue & Forecasts
6.2.1 By Region – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2018-2023
6.2.2 By Region – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2024-2029
6.2.3 By Region – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share, 2018-2029
6.3 By Region – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales & Forecasts
6.3.1 By Region – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2018-2023
6.3.2 By Region – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2024-2029
6.3.3 By Region – Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2018-2029
6.4.2 By Country – North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2018-2029
6.4.3 US 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.4.4 Canada 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.4.5 Mexico 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2018-2029
6.5.2 By Country – Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2018-2029
6.5.3 Germany 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.5.4 France 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.5.5 U.K. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.5.6 Italy 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.5.7 Russia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.5.8 Nordic Countries 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.5.9 Benelux 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2018-2029
6.6.2 By Region – Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2018-2029
6.6.3 China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.6.4 Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.6.5 South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.6.6 Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.6.7 India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2018-2029
6.7.2 By Country – South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2018-2029
6.7.3 Brazil 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.7.4 Argentina 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, 2018-2029
6.8.3 Turkey 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.8.4 Israel 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.8.5 Saudi Arabia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
6.8.6 UAE 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Major Product Offerings
7.1.4 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales and Revenue in Global (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Kangtai
7.2.1 Kangtai Company Summary
7.2.2 Kangtai Business Overview
7.2.3 Kangtai 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Major Product Offerings
7.2.4 Kangtai 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales and Revenue in Global (2018-2023)
7.2.5 Kangtai Key News & Latest Developments
7.3 Walvax Biotechnology
7.3.1 Walvax Biotechnology Company Summary
7.3.2 Walvax Biotechnology Business Overview
7.3.3 Walvax Biotechnology 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Major Product Offerings
7.3.4 Walvax Biotechnology 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales and Revenue in Global (2018-2023)
7.3.5 Walvax Biotechnology Key News & Latest Developments
8 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Production Capacity, Analysis
8.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Production Capacity, 2018-2029
8.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Supply Chain Analysis
10.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Industry Value Chain
10.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Upstream Market
10.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
| 【13価肺炎球菌多糖体複合体ワクチンについて】 13価肺炎球菌多糖体複合体ワクチンは、小児や高齢者を含む多くの人々に対して、肺炎球菌による感染症を予防するために用いられる重要なワクチンのひとつです。肺炎球菌は、細菌性肺炎や髄膜炎、中耳炎、喉頭蓋炎といった重篤な感染症を引き起こす原因となる病原体です。このワクチンは、肺炎球菌の特定の13種類の血清型による感染からの防御を提供します。 本ワクチンの最も大きな特徴は、肺炎球菌の表面に存在する多糖体を利用した点です。多糖体とは、単糖が多数結合した炭水化物の一種で、肺炎球菌の外膜に存在します。これらの多糖体は、病原体が免疫系の認識をかいくぐる際に重要な役割を果たしています。しかし、単独の多糖体ワクチンは、乳児や幼児に十分な免疫応答を引き起こさないため、複合体ワクチンが開発されました。具体的には、多糖体にタンパク質を結合させることにより、免疫系の働きを強化する方法が取られています。このようにして、免疫系のB細胞は、特定の肺炎球菌の多糖体に対する抗体を効果的に生成し、病原体に対抗する準備を整えることができます。 このワクチンは、新生児から高齢者まで幅広い年齢層に接種されますが、その適応については、特にリスクが高い群体に対して重点が置かれています。例えば、慢性閉塞性肺疾患（COPD）や心血管疾患、糖尿病などの基礎疾患を有する高齢者は、肺炎球菌による感染症にかかりやすいとされています。また、免疫抑制状態にある方（がん治療を受けている人など）にも推奨されます。さらに、ワクチン接種は、集団免疫の観点からも重要であり、接種を受けた人々が感染源になるリスクを低下させることができます。 13価肺炎球菌多糖体複合体ワクチンには、感染症予防の効果はもちろんのこと、重症化のリスクを低減させるといったメリットも存在します。実際の臨床研究では、ワクチン接種を受けた集団において肺炎球菌による肺炎やその他の感染症の発生率が有意に低いことが示されています。そのため、ワクチン接種は公衆衛生の観点からも重要視されています。 使用される種類に関しては、13価肺炎球菌多糖体複合体ワクチンは、米国疾病管理予防センター（CDC）や国際的な健康機関で推奨される標準的な接種スケジュールに基づいて投与されます。このワクチンは主に筋肉内注射として実施され、通常すぐに効果を発揮するわけではなく、体内での抗体形成には数週間を要します。なお、ワクチン接種によって副反応が出ることもありますが、これらは通常軽度で一時的なものであり、接種による利益がリスクを上回るとされています。 現在では、肺炎球菌ワクチンに関連する技術も進化を遂げています。例えば、高度な製造技術や、ワクチンの効果を高めるための添加剤（アジュバント）に関する研究が進められています。これにより、新たなワクチン候補の開発や、既存のワクチンの改善につながる可能性があります。加えて、肺炎球菌以外の病原体に対する複合体ワクチンの開発も進められており、今後の展開に期待が持てます。 総じて、13価肺炎球菌多糖体複合体ワクチンは、肺炎球菌感染による病気から人々を守るために重要な役割を果たしています。ワクチン接種は個人のみならず、コミュニティ全体における感染症予防の観点からも有効であり、健康生活を支えるための基盤となる医療介入の一つです。これからも継続的な研究や投与の普及が求められ、さらなる感染症予防につながることが期待されています。 |
